News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Both Are Roche (RHHBY)'s Drugs, But Which One Could Save The U.S. $3 Billion?


6/4/2014 9:31:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The U.S. could save almost $3 billion a year if Medicare patients were given Avastin instead of Lucentis to treat two diseases that could lead to blindness, according to a study in the journal Health Affairs. Both treatments are made by Basel, Switzerland-based Roche Holding AG, and work similarly in treating neovascular age-related macular degeneration and diabetic macular edema by targeting the retinal bleeding and swelling that’s the leading cause of blindness in older Americans. Lucentis, though, costs more than $2,000 per dose, or 40 times more than Avastin. Treatments for these eye diseases account for about one-sixth of the Medicare Part B budget, according to the report.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at USA Today
Read at News Release


comments powered by Disqus
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES